Plasma <i>p</i> ‐Tau217 assay performance in Japan: from preclinical/prodromal cohort to DMT registry

These results indicate that plasma p-tau217 alone, or combinations of plasma Aβ biomarkers and p-tau217, are effective in predicting Aβ-PET positivity in preclinical and prodromal AD. The ability of the p-tau217 plasma assays to prescreen eligible patients and monitor the efficacy of anti-Aβ antibodies and other DMTs is also being tested in a real-world setting in the Japanese early symptomatic AD patient registry.